Fatal EBV-related post-transplant lymphoproliferative disorder (LPD) after matched related donor nonmyeloablative peripheral blood progenitor cell transplant

Bone Marrow Transplantation

Volumn 31, Issue 3, 2003, Pages 219-222

  Zamkoff, K W ^a   Bergman, S ^a   Beaty, M W ^a   Buss, D H ^a   Pettenati, M J ^a   Hurd, D D ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

EBV; Non myeloablative transplant; Post transplant lymphoproliferative disorder

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; CARBOPLATIN; CD20 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD79A ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; EPSTEIN BARR VIRUS ANTIGEN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; LEUKOSIALIN; PREDNISONE; THYMOCYTE ANTIBODY; VINCRISTINE; VIRUS RNA;

ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; CELL INFILTRATION; CONTROLLED STUDY; CYTOCHEMISTRY; DEATH; DISEASE SEVERITY; DONOR; EPSTEIN BARR VIRUS; FATALITY; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLAST; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; KIDNEY FAILURE; LACTIC ACIDOSIS; LARGE CELL LYMPHOMA; LIVER BIOPSY; LIVER PARENCHYMA; LYMPHOCYTIC INFILTRATION; LYMPHOPROLIFERATIVE DISEASE; MALE; OLIGURIA; PERIPHERAL BLOOD STEM CELL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENT DISEASE; RELATIVE; SEROLOGY; TUMOR CELL; VIRUS INFECTION;

ADULT; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPSTEIN-BARR VIRUS INFECTIONS; FATAL OUTCOME; HUMANS; LIVER; LYMPH NODES; LYMPHOMA, T-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; PREDNISONE; STEM CELL TRANSPLANTATION; VINCRISTINE;

EID: 0037293517     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703838     Document Type: Article

References (12)

1. O'Reilly RJ, Small TN, Papadopoulos E et al. Biology and adoptive therapy of Epstein Barr virus associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997; 157: 195-216.
2. Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208-2216.
3. Ho AYL, Adams S, Shaikh H et al. Fatal donor derived Epstein-Barr virus-associated post-transplant lymphoproliferative disorder following reduced intensity volunteer related bone marrow transplant for myelodysplastic syndrome. Bone Marrow Transplant 2002; 29: 867-869.
4. Milpied N, Coste-Burel M, Accard F et al. Epstein-Barr virus associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 1999; 23: 629-630.
5. Bishop MR. Non-myeloablative allogeneic hematopoietic stem cell transplantation as adoptive cellular therapy. In: Rosenberg SA (ed.). Principles and Practice of Biologic Therapy of Cancer. Lippincott Williams and Wilkins Healthcare: New York, 2001, pp 1-9.
6. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998; 91: 756-763.
7. Spitzer TR, McAfee SL, Sackstein R et al. Induction of mixed chimerism and potent anti-tumor responses following non-myeloablative conditioning therapy and HLA matched and mismatched donor bone marrow transplantation for refractory hematologic malignancies. Blood 1998; 92: 519 (abstract 2134).
8. Eiermann TH, Lambrecht P, Zander AR. Monitoring antithymocyte globulin (ATG) in bone marrow recipients. Bone Marrow Transplant 1999; 23: 779-781.
9. Remberger M, Svahn BM, Lofgren C, Ringden O. Effect on cytokine release and graft versus host disease of different T cell antibodies during conditioning for unrelated hematopoietic stem cell transplant. Bone Marrow Transplant 1999; 24: 823-830.
10. Gulley ML. Molecular diagnosis of Epstein Barr virus related diseases. J Mol Diag 2001; 3: 1-10.
11. Strauss SE, Cohen JI, Tosato G, Meier J. Epstein Barr Virus infections: biology, pathogenesis and management. Ann Intern Med 1993; 118: 45-58.
12. van Esser JWJ, Niesters HGM, van der Holt B et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364-4369.